TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Median length of time to alleviation of major symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prognostic discrimination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response duration with onabotulinumtoxinA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Berg Balance Scale improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of cardiovascular adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: CD3(+)CD4(+) lymphocyte count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: GSH/GSSG ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severity of urgency symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severity of dry mouth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean size of the initial erosion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: linear speed of reepithelialization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: surface speed of reepithelialization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coronary Flow Reserve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Resistive Reserve Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: New active lesions developed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Annualized relapse rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Relapse-free patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: mean decayed, missed and filled surface (DMFS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: odds ratio for developing dentine lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BOLD activation in response to alcohol cues
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: AD symptom count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brachial artery endothelial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Low-density lipoprotein-cholesterol (LDL-C) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incremental costs per QALY gained
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Survival rate using reoperation or progression of osteoarthritis
Endpoint domain: Mortality/survival
Primary endpoint: MHHS scores after 2 years of follow-up
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: reactivation of previously positive patch test reactions
Endpoint domain: Adverse events/effects
Primary endpoint: ulcer parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean serum 25(OH)D concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportions of 25(OH)D insufficient patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of vertebral fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rate of non-vertebral weight-bearing bone fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence rates of nausea
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence rates of retching
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of randomized women using HT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean 4-month reduction in HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Histamine release from peripheral blood leukocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Expression of Syk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: FcRbeta/FcepsilonRIalpha ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Initial device connection rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of gestational diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Response rates at 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: mean peak systolic flow velocities (PSVs) of the ophthalmic artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: mean PSV and resistive indices of the CRA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: serum levels of total cholesterol, low‐density lipoprotein cholesterol and triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Correlation of MRI and arthroscopy in detecting TFCC lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of MRI in detecting complete scapholunate ligament tears
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of MRI in detecting complete scapholunate ligament tears
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient health outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinician‐Administered PTSD Scale score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proton pump inhibitor therapy reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Heartburn symptom score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Esophageal acid reflux decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Overall treatment satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Best-corrected visual acuity (BCVA) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ulcer pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improve memory and executive capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: asthma specific quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mucocutaneous toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Average length of admission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Psychosocial Stress Scale (PSS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall Life Satisfaction (OLS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adjusted hemoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Anemia reduction percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cesarean section
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Instrumental extraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: CAVI decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum triglycerides decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: willingness to repeat the procedure
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Remnant lipoprotein levels (RLP-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of moderate to severe COPD exacerbations per patient
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Net proportion of patients with a relevant improvement on SGRQ total score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Global LV volume (LVV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Wall motion (WM) abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of new diffusion-weighted imaging lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Volume of lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Physical activity levels (step count)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ischemic burden during exposure to diesel exhaust
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Acute release of endothelial tissue plasminogen activator
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Baseline potassium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ECG effects (U waves, T-wave amplitude, Q-Tc interval)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: TLF within 1 year
Endpoint domain: Mortality/survival
Primary endpoint: NTX level reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DeltaTIMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: DeltaMBG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Transferrin saturation (TSAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EPO dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in resting and submaximal heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximal work load after 3 weeks of training
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VO(2)max values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Energy intake during treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Continuation of MAD for 6 months or more
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Residual Spherical Error (MRSE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visualization of the four-chamber view
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visualization of the left outflow tract
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visualization of the right outflow tract
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repigmentation in the head and neck area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Frequency of severe postpartum haemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Decrease in haemoglobin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Complete Response plus Partial Response (CR + PR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life decrements
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: peak oxygen consumption (PeakVO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: activation
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Risk of gallbladder disease or surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: limitation of daily activities due to leg pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rates of major adverse cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Consumer acceptability of yogurt
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: incidence of ventricular fibrillation requiring defibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: suppression of wheals and flares
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean change in ODI at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in VAS at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients achieving ≥10-point improvement in ODI
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: mean central subfield thickness reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of ranibizumab injections
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Confirmed exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pseudoexacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PPE use intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective improvement endoscopically demonstrated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functioning
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Variation of FA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation of CAT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days of Severe Neutropenia (DSN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Decline of cognition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: ACQ score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily inhaled corticosteroid dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nitric oxide-mediated vasodilation improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in geometric centres (GCs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Bladder capacity (BC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Vesicoureteral reflux (VUR) resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Decline in PI of uterine artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Rate of remission (MADRS total score <= 12)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of depressive relapse
Endpoint domain: Adverse events/effects
Primary endpoint: Saltiness scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of hormone treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence or absence of testes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Future fertility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of older adults observed being active in parks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in prevalence of anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in hemoglobin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Accuracy in estimating side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Risk of pulmonary embolism estimation
Endpoint domain: Adverse events/effects
Primary endpoint: serum LDL cholesterol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Nonstimulated salivary flow rate (SFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stimulated salivary flow rate (SFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of removed pleural effusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioelectrical impedance change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: death or heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Conversion to type 2 diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Control of dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma creatinine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Diagnostic yield of CB compared to forceps biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Size of samples obtained by CB compared to forceps biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bleeding grades reported after CB and forceps biopsy
Endpoint domain: Adverse events/effects
Primary endpoint: Role of adjunctive corticosteroids and M. w immunotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: actual blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: EASI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Itch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FMS mastery improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean VPA increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor size increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mental health measures
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Physical health measures
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: nasopharyngeal local control rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cervical lymph nodes local control rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of mature oocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: embryo morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time until occurrence of the first upper respiratory tract infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Alpha diversity (species richness)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood of improvement with placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of ischemic stroke
Endpoint domain: Mortality/survival
Primary endpoint: Recurrence of symptomatic intracerebral hemorrhage
Endpoint domain: Mortality/survival
Primary endpoint: Probability of survival on day 28
Endpoint domain: Mortality/survival
Primary endpoint: Probability of survival on day 90
Endpoint domain: Mortality/survival
Primary endpoint: criteria fulfillment rate of accurate dyslipidaemia management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrent ischemic events or death
Endpoint domain: Mortality/survival
Primary endpoint: incidence rate of low cardiac output episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: reduction in cardiac index at 6 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: increase in inotropic support in the first 12 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total tramadol amounts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased sleep disturbances
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Decreased burden on parents
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Reduction in anxiety level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ventilator-associated pneumonia (VAP) incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time of hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: days of moderate physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes